Antibody-mediated rejection (AMR) is a recognized cause of allograft dysfunction in lung
transplant recipients. Unlike AMR in other solid-organ transplant recipients, there are no …

With an improved median survival of 6.2 years, lung transplantation has become an
increasingly acceptable treatment option for end-stage lung disease. Besides survival …

Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Rationale: Despite increasing evidence about the role of donor-specific human leukocyte
antigen (HLA) antibodies in transplant outcomes, the incidence and impact of de novo donor …

Steady-state alveolar macrophages (AMs) are long-lived lung-resident macrophages with
sentinel function. Evidence suggests that AM precursors originate during embryogenesis …

The number of lung transplantations is progressively increasing worldwide, providing new
challenges to interprofessional teams and the intensive care units. The outcome of lung …

Our understanding of the role of B cells in organ transplantation remains incomplete and
continues to grow. The majority of research has focused on the detrimental role of antibodies …

A growing number of patients with end-stage lung disease have benefited from lung
transplantation (LT). Improvements in organ procurement, surgical techniques and intensive …

Therapeutic plasma exchange (TPE) is the extracorporeal technique performed in an
apheresis device were patient's plasma is separated from whole blood and removed, while …

The development of de novo donor-specific HLA antibodies (dnDSA) after transplantation is
associated with graft failure, mortality, and cost. There is no effective therapeutic intervention …